Christian Latrémouille
March 05, 2021
CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,today announces the appointment ofProfessor Christian Latrémouille as Director of Surgical Affairs.
Doctor of Medicine specialized in Heart Surgery, Christian Latrémouilleis a Professor at Paris University, formed by the recentmerger of Paris-Descartes (Paris V) and Paris-Diderot (Paris VII) Universities.
Before joiningCARMAT, Christian Latrémouillewas, since 2017,Head of the Cardiovascular Surgery Department at the Georges Pompidou European Hospital in Paris.He began his career in 1993 asSenior Specialist Registrarwithin Prof. Alain Carpentier's prestigious Cardiac Surgery department at theBroussaisHospital in Paris. Uponvalidation of a PhD in xenotransplantation, in 1995 he took charge of the heart transplant program.Initially Clinical Lecturer in 1995 and then University Lecturer in 2000, in 2004 he was appointed Associate Professorat Paris-Descartes University, university chair ofClinical Anatomy andhospital chair ofadult Cardiac Surgery.Since then, he has been entrusted with the preclinical development phase of theCARMATbioprosthetic total artificial heart.
Building on this experience, he performed the world's first-in-man implantation of the CARMAT heart on December 18,2013.He then becamePrincipalInvestigatorof the CARMAT heart's safety and feasibility study. Subsequently, during thePIVOTAL study, he continued as Proctor Principal, ensuring the training of all the new teams joining the project.
This career path makes him the only heart surgeon in the world to have participated inthe CARMAT heart's entire clinical assessment process.
"I particularly appreciate the trust put in me by allowing me to join CARMAT's teams.The recent granting of CE marking and the prospect ofsoon performing the first human implants in the United Statesrepresent a major milestone in the development of CARMAT.Drawing on my experience, I am pleased to be able to take part in the final leg of this projectin order to enable as many patients as possible to benefitfrom this innovative, ambitious andaccomplished technology whose notion of quality of life remains the primary purpose", says Prof. Latrémouille, CARMAT's new Director of Surgical Affairs.
Stéphane Piat, Chief Executive Officer ofCARMAT, adds:"It is an immense pleasure to welcome Christian Latrémouilleto our management team. His arrival marksthe completion of the structuring of our Management Committee with a view to preparing the launch of ourAeson device. Hissurgical expertise coupled with the unique experience he has acquired with CARMAT will be pivotal to the successful ramping up of our commercial launch. In his new role, Christian Latrémouillewill accompany and oversee hospitals from the training phase through to patient treatment".
About CARMAT: the world's most advanced total artificial heart project
A credible response to end-stage heart failure:CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, composed of the implantable bioprosthesis and its portable external power supply system to which it is continuously connected, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.
Doctor of Medicine specialized in Heart Surgery, Christian Latrémouilleis a Professor at Paris University, formed by the recentmerger of Paris-Descartes (Paris V) and Paris-Diderot (Paris VII) Universities.
Before joiningCARMAT, Christian Latrémouillewas, since 2017,Head of the Cardiovascular Surgery Department at the Georges Pompidou European Hospital in Paris.He began his career in 1993 asSenior Specialist Registrarwithin Prof. Alain Carpentier's prestigious Cardiac Surgery department at theBroussaisHospital in Paris. Uponvalidation of a PhD in xenotransplantation, in 1995 he took charge of the heart transplant program.Initially Clinical Lecturer in 1995 and then University Lecturer in 2000, in 2004 he was appointed Associate Professorat Paris-Descartes University, university chair ofClinical Anatomy andhospital chair ofadult Cardiac Surgery.Since then, he has been entrusted with the preclinical development phase of theCARMATbioprosthetic total artificial heart.
Building on this experience, he performed the world's first-in-man implantation of the CARMAT heart on December 18,2013.He then becamePrincipalInvestigatorof the CARMAT heart's safety and feasibility study. Subsequently, during thePIVOTAL study, he continued as Proctor Principal, ensuring the training of all the new teams joining the project.
This career path makes him the only heart surgeon in the world to have participated inthe CARMAT heart's entire clinical assessment process.
"I particularly appreciate the trust put in me by allowing me to join CARMAT's teams.The recent granting of CE marking and the prospect ofsoon performing the first human implants in the United Statesrepresent a major milestone in the development of CARMAT.Drawing on my experience, I am pleased to be able to take part in the final leg of this projectin order to enable as many patients as possible to benefitfrom this innovative, ambitious andaccomplished technology whose notion of quality of life remains the primary purpose", says Prof. Latrémouille, CARMAT's new Director of Surgical Affairs.
Stéphane Piat, Chief Executive Officer ofCARMAT, adds:"It is an immense pleasure to welcome Christian Latrémouilleto our management team. His arrival marksthe completion of the structuring of our Management Committee with a view to preparing the launch of ourAeson device. Hissurgical expertise coupled with the unique experience he has acquired with CARMAT will be pivotal to the successful ramping up of our commercial launch. In his new role, Christian Latrémouillewill accompany and oversee hospitals from the training phase through to patient treatment".
About CARMAT: the world's most advanced total artificial heart project
A credible response to end-stage heart failure:CARMAT aims to eventually provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. By pursuing the development of its total artificial heart, composed of the implantable bioprosthesis and its portable external power supply system to which it is continuously connected, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from irreversible end-stage heart failure, the most seriously affected of the 20 million patients with this progressive disease in Europe and the United States.